Amgen Inc. (NASDAQ:AMGN)‘s stock had its “buy” rating reissued by stock analysts at Jefferies Group LLC in a research note issued on Monday. They currently have a $200.00 price objective on the medical research company’s stock. Jefferies Group LLC’s price target indicates a potential upside of 7.67% from the stock’s current price.

Several other research firms have also weighed in on AMGN. ValuEngine lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $203.00 price objective (up previously from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. BMO Capital Markets lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 26th. Finally, Argus upped their price objective on shares of Amgen from $180.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. Amgen presently has a consensus rating of “Buy” and a consensus price target of $186.39.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.84 EPS.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/25/jefferies-group-llc-reiterates-buy-rating-for-amgen-inc-amgn.html.

Several large investors have recently added to or reduced their stakes in AMGN. OLD Point Trust & Financial Services N A lifted its holdings in shares of Amgen by 5.9% during the 1st quarter. OLD Point Trust & Financial Services N A now owns 25,793 shares of the medical research company’s stock worth $4,232,000 after acquiring an additional 1,433 shares during the period. Abner Herrman & Brock LLC lifted its holdings in shares of Amgen by 8.3% during the 1st quarter. Abner Herrman & Brock LLC now owns 41,442 shares of the medical research company’s stock worth $6,799,000 after acquiring an additional 3,181 shares during the period. Nippon Life Insurance Co. lifted its holdings in shares of Amgen by 6.1% during the 1st quarter. Nippon Life Insurance Co. now owns 29,664 shares of the medical research company’s stock worth $4,867,000 after acquiring an additional 1,718 shares during the period. Raub Brock Capital Management LP lifted its holdings in shares of Amgen by 9.4% during the 1st quarter. Raub Brock Capital Management LP now owns 77,723 shares of the medical research company’s stock worth $12,752,000 after acquiring an additional 6,689 shares during the period. Finally, Hudson Valley Investment Advisors Inc. ADV lifted its holdings in shares of Amgen by 3.6% during the 1st quarter. Hudson Valley Investment Advisors Inc. ADV now owns 11,395 shares of the medical research company’s stock worth $1,870,000 after acquiring an additional 400 shares during the period. 78.10% of the stock is owned by institutional investors.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.